Resistance Training with Vascular Occlusion in Inclusion Body Myositis: A Case Study

Author(s):Show less -

Gualano, Bruno ^[1] ; Neves, Jr., Manoel ^[2] ; Lima, Fernanda Rodrigues ^[2] ; De Sa Pinto, Ana Lucia ^[2] ; Laurentino, Gilberto ^[1] ; Borges, Claudia ^[2] ; Baptista, Luciana ^[3] ; Artioli, Guilherme Giannini ^[1] ; Aoki, Marcelo Saldanha ^{[4, 5]} ; Moriscot, Anselmo ^{[4, 5]} ; Lancha, Jr., Antonio Herbert ^[1] ; Bonfa, Eloisa ^[2] ; Ugrinowitsch, Carlos ^[1]

Affiliation

^[1] Univ Sao Paulo, Sch Phys Educ & Sport, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Sch Med, Div Rheumatol, Sao Paulo - Brazil

^[3] Hosp Nove de Julho, Sao Paulo - Brazil

^[4] Univ Sao Paulo, Sch Arts Sci & Humanities, Sao Paulo - Brazil

^[5] Univ Sao Paulo, Inst Biomed Sci, Sao Paulo - Brazil

• Document type: Journal article
• Source: MEDICINE AND SCIENCE IN SPORTS AND EXERCISE; v. 42, n. 2, p. 250-254, FEB 2010.
• Web of Science Citations: 50

Abstract

GUALANO, B., M. NEVES JR, F. R. LIMA, A. L. PINTO, G. LAURENTINO, C. BORGES, L. BAPTISTA, G. G. ARTIOLI, M. S. AOKI, A. MORISCOT, A. H. LANCHA JR, E. BONFA, and C. UGRINOWITSCH. Resistance Training with Vascular Occlusion in Inclusion Body Myositis: A Case Study. Med Sci. Spot-is Exerc., Vol. 42, No. 2, pp. 250-254, 2010. Inclusion body myositis (IBM) is a rare idiopathic inflammatory myopathy that produces remarkable muscle weakness. Resistance training with vascular occlusion has been shown to improve muscle strength and cross-sectional area in other muscle wasting conditions. Purpose: We evaluated the efficacy of a moderate-intensity resistance training program combined with vascular occlusion by examining functional capacity, muscle morphology, and changes in the expression of genes related to muscle protein synthesis and proteolysis in a patient with IBM. Methods: A 65-yr-old man with IBM resistant to all proposed treatments underwent resistance training with vascular occlusion for 12 wk. Leg press one-repetition maximum; thigh cross-sectional area; balance, mobility, and muscle function; quality of life; and blood markers of inflammation and muscle damage were assessed at baseline and after the 12-wk program. The messenger RNA (mRNA) expression levels of mechanogrowth factor, mammalian target of rapamycin, atrogin-1, and muscle RING finger-1 were also quantified. Results: After the 12-wk training program, the patient's leg press one-repetition maximum, balance and mobility function, and thigh cross-sectional area increased 15.9%, 60%, and 4.7%, respectively. All Short Form-36 Health Survey Questionnaire subscales demonstrated improvements as well, varying from 18% to 600%. mRNA expression of mechanogrowth factor increased 3.97-fold, whereas that of atrogin-1 decreased 0.62-fold. Muscle RING finger-1 and mammalian target of rapamycin mRNA levels were only slightly altered, 1.18- and 1.28-fold, respectively. Importantly, the exercise did not induce disease flare. Conclusions: We describe a novel, and likely the first, nonpharmacological therapeutic tool that might be able to counteract the muscle atrophy and the declining strength that usually occur in IBM. (AU)